Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025
Sobi to Showcase New Insights on pegcetacoplan at ASN Kidney Week 2025
Sobi®, a global biopharmaceutical company, has announced its participation in the ASN Kidney Week 2025, taking place from November 5 to 9 in Houston, Texas. The company will share one oral presentation and six poster presentations regarding Aspaveli/Empaveli (pegcetacoplan) for C3 Glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), alongside three poster presentations on NASP (Nanoencapsulated Sirolimus plus pegadricase) for uncontrolled gout.
Key Findings on pegcetacoplan
The data presented on pegcetacoplan highlights its sustained efficacy over a one-year period in patients suffering from C3G and primary IC-MPGN. Dr. Lydia Abad-Franch, Head of Research and Development and Chief Medical Officer at Sobi, noted that patients receiving this treatment achieved significant reductions in proteinuria, which was consistent regardless of their immunosuppressant use or initial proteinuria levels. Remarkably, one-third of patients attained complete remission by week 26, in stark contrast to a mere 3% achieved through the placebo, with these positive results maintained for the entire year. Those patients who transitioned from placebo to treatment demonstrated substantial improvements, underscoring the transformative potential of pegcetacoplan in managing these complex kidney disorders.
NASP’s Contribution to Kidney Health
In addition to pegcetacoplan, Sobi will present findings related to NASP, which effectively maintained stable renal function throughout a six-month observational study. Among individuals with uncontrolled gout and stage 3 chronic kidney disease, a higher percentage exhibited improved CKD stages compared to those on placebo. Furthermore, NASP was associated with a reduction in gout-related symptoms, and the treatment was well-tolerated among participants.
Presentation Highlights
The ASN Kidney Week will feature several key sessions, including:
- - Sustained proteinuria reduction: The Phase 3 VALIANT trial results, showcasing pegcetacoplan's long-term efficacy in reducing proteinuria. This oral presentation will be led by Dr. Carla M. Nester and is scheduled for November 8, from 4:50 PM to 5:00 PM (CT).
- - Impact on pediatric patients: A detailed poster presentation by Dr. Larry A. Greenbaum discussing the efficacy of pegcetacoplan in maintaining proteinuria reduction among pediatric patients.
- - Patient perspectives: Dr. Sayna Nourouzi will present a thematic analysis that explores the unmet care needs within the C3G and primary IC-MPGN communities, providing vital qualitative insights.
About Sobi and Its Mission
Sobi, listed on Nasdaq Stockholm (STO: SOBI), continues to pioneer treatments for rare diseases. With an expansive global presence in the biopharmaceutical sphere, it endeavours to improve the quality of life for patients facing severe health challenges. The company reported revenue exceeding SEK 26 billion in 2024, showcasing its commitment to advancing medical innovations.
At ASN Kidney Week, Sobi underscores its dedication to addressing critical unmet medical needs through its innovative therapies like pegcetacoplan and NASP, aiming to transform patient care for those battling rare and debilitating kidney diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.